These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. [A study on hepatic iron overload in chronic hepatitis C patients]. Bomfim EA; Pereirade de Oliveira AC; Paraná R; Schinoni MI Acta Gastroenterol Latinoam; 2013 Sep; 43(3):212-7. PubMed ID: 24303687 [TBL] [Abstract][Full Text] [Related]
28. Hepatic fibrogenesis: from within and outwith. Henderson NC; Forbes SJ Toxicology; 2008 Dec; 254(3):130-5. PubMed ID: 18824072 [TBL] [Abstract][Full Text] [Related]
29. The risk factors of fibrosis in nonalcoholic steatohepatitis. Fierbinţeanu-Braticevici C; Bengus A; Neamţu M; Usvat R Rom J Intern Med; 2002; 40(1-4):81-8. PubMed ID: 15526543 [TBL] [Abstract][Full Text] [Related]
30. Wild Edible Fruit of Prunus nepalensis Ser. (Steud), a Potential Source of Antioxidants, Ameliorates Iron Overload-Induced Hepatotoxicity and Liver Fibrosis in Mice. Chaudhuri D; Ghate NB; Panja S; Das A; Mandal N PLoS One; 2015; 10(12):e0144280. PubMed ID: 26633891 [TBL] [Abstract][Full Text] [Related]
31. Liver cirrhosis as a consequence of iron overload caused by hereditary nonspherocytic hemolytic anemia. Hilgard P; Gerken G World J Gastroenterol; 2005 Feb; 11(8):1241-4. PubMed ID: 15754414 [TBL] [Abstract][Full Text] [Related]
32. Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets. Li LX; Guo FF; Liu H; Zeng T Cell Mol Life Sci; 2022 Mar; 79(4):201. PubMed ID: 35325321 [TBL] [Abstract][Full Text] [Related]
33. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. Reeves HL; Burt AD; Wood S; Day CP J Hepatol; 1996 Nov; 25(5):677-83. PubMed ID: 8938545 [TBL] [Abstract][Full Text] [Related]
34. Iron as a hepatotoxin. Stål P Dig Dis; 1995; 13(4):205-22. PubMed ID: 8521607 [TBL] [Abstract][Full Text] [Related]
35. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Bugianesi E; Manzini P; D'Antico S; Vanni E; Longo F; Leone N; Massarenti P; Piga A; Marchesini G; Rizzetto M Hepatology; 2004 Jan; 39(1):179-87. PubMed ID: 14752836 [TBL] [Abstract][Full Text] [Related]
36. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Adams PC Am J Gastroenterol; 2001 Feb; 96(2):567-9. PubMed ID: 11232708 [TBL] [Abstract][Full Text] [Related]
37. Strategies to prevent and reverse liver fibrosis in humans and laboratory animals. Chen RJ; Wu HH; Wang YJ Arch Toxicol; 2015 Oct; 89(10):1727-50. PubMed ID: 25963329 [TBL] [Abstract][Full Text] [Related]
38. [Pathophysiology of hepatic fibrosis]. Vaĺková M Vnitr Lek; 2002 Jan; 48(1):27-33. PubMed ID: 11852583 [TBL] [Abstract][Full Text] [Related]
39. Hepatic injury in chronic iron overload. Role of lipid peroxidation. Bacon BR; Britton RS Chem Biol Interact; 1989; 70(3-4):183-226. PubMed ID: 2663196 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of iron status in patients with chronic hepatitis C. Sartori M; Andorno S; La Terra G; Boldorini R; Leone F; Pittau S; Zecchina G; Aglietta M; Saglio G Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):396-401. PubMed ID: 9789136 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]